ReviewHeart (British Cardiac Society)2018
Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.
Review in Heart (British Cardiac Society), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Pooled it
- Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.Thoracic cancer · 2021Trial
- Cardiovascular Imaging for the Early Detection of Cardiotoxicity from Emerging Cancer Therapies: Mechanistic Insights Across the Pediatric and Adult Spectrum.Journal of personalized medicine · 2026Review
- Signals of pericardial and myocardial events associated with antiangiogenic drugs: a disproportionality analysis on FAERSEuropean journal of clinical pharmacology · 2026Article
- Insights and perspectives into the etiology of TKI-induced cardiotoxicity.ASPET discovery · 2026Article
- Innate immune cells in vascular lesions: mechanism and significance of diversified immune regulation.Annals of medicine · 2025Review
- A pharmacovigilance study of thromboembolism events associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors based on FAERS database.Scientific reports · 2025Article
- Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma.Clinical journal of oncology nursing · 2025Review
- Apatinib-Induced Hypertension Correlates with Improved Prognosis in Solid Tumor Patients.Cardiovascular toxicology · 2025Article
- Acute vascular and cardiac effects of lenvatinib in mice.Cardio-oncology (London, England) · 2025Article
- Antiangiogenic potential of phytochemicals from Clerodendrum inerme (L.) Gaertn investigated through in silico and quantum computational methods.Molecular diversity · 2025Article
- Mineralocorticoid Receptor in Endothelial Cells Contributes to Vascular Endothelial Growth Factor Receptor Inhibitor-Induced Vascular and Kidney Damage.American journal of hypertension · 2025Article
- Theoretical Model for In Vivo Induction of Chemotherapy Sensitization Using miRNA Packaged in Distinct Layered Liposomes.Journal of functional biomaterials · 2024Article
- Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors.Clinical science (London, England : 1979) · 2024Article
- Management of patients with extensive locally advanced thyroid cancer: results of multimodal treatments.Journal of endocrinological investigation · 2024Article
- Onco-Hypertension: A Continuously Developing Field between Cancer and Hypertension.International journal of molecular sciences · 2024Review
- Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model.Pharmaceuticals (Basel, Switzerland) · 2023Article
- High incidence and reversible bradycardia events following alectinib initiation.Thoracic cancer · 2023Article
- Cardiovascular Toxicity Induced by Vascular Endothelial Growth Factor Inhibitors.Life (Basel, Switzerland) · 2023Review
- Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib.Drug design, development and therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Clinical outcomes for patients with a wide range of malignancies have improved substantially over the last two decades. Tyrosine kinase inhibitors (TKIs) are potent signalling cascade inhibitors and have been responsible for significant advances in cancer therapy. By inhibiting vascular endothelial growth factor receptor (VEGFR)-mediated tumour blood vessel growth, VEGFR-TKIs have become a mainstay of treatment for a number of solid malignancies. However, the incidence of VEGFR-TKI-associated cardiovascular toxicity is substantial and previously under-recognised. Almost all patients have an acute rise in blood pressure, and the majority develop hypertension. They are associated with the development of left ventricular systolic dysfunction (LVSD), heart failure and myocardial ischaemia and can have effects on myocardial repolarisation. Attention should be given to rigorous baseline assessment of patients prior to commencing VEGFR-TKIs, with careful consideration of baseline cardiovascular risk factors. Baseline blood pressure measurement, ECG and cardiac imaging should be performed routinely. Hypertension management currently follows national guidelines, but there may be a future role forendothelin-1 antagonism in the prevention or treatment of VEGFR-TKI-associated hypertension. VEGFR-TKI-associated LVSD appears to be independent of dose and is reversible. Patients who develop LVSD and heart failure should be managed with conventional heart failure therapies, but the role of prophylactic therapy is yet to be defined. Serial monitoring of left ventricular function and QT interval require better standardisation and coordinated care. Management of these complex patients requires collaborative, cardio-oncology care to allow the true therapeutic potential from cancer treatment while minimising competing cardiovascular effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.